Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213339 | 0.68 | — | — | |
| SCHEMBL15001582 | 0.63 | HTR2A (0.41) | HTR2AHTR2CCHRNB2CHRNA4KDM4E | |
| SCHEMBL343286 | 0.62 | ADRB2 (0.36) | HTR2AHTR2CCHRNB2CHRNA4KDM4E | |
| SCHEMBL24722874 | 0.62 | HTR2C (0.39) | HTR2AHTR2CCHRNB2CHRNA4KDM4E | |
| SCHEMBL5779110 | 0.60 | HTR2A (0.39) | HTR2AHTR2CCHRNB2CHRNA4 | |
| SCHEMBL2002227 | 0.60 | HTR2C (0.39) | HTR2AHTR2CCHRNB2CHRNA4 | |
| SCHEMBL25034229 | 0.59 | HTR2C (0.47) | HTR2AHTR2CCHRNB2CHRNA4KDM4E | |
| SCHEMBL24417833 | 0.59 | HTR2C (0.37) | HTR2AHTR2C | |
| SCHEMBL20517214 | 0.59 | HTR2C (0.37) | HTR2AHTR2CCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL5774503 | 0.59 | HTR2C (0.38) | HTR2AHTR2CCHRNB2CHRNA4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | HTR2A 3672/4885HTR2C 4513/4885CHRNB2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.